SPTLC1 inhibits cell growth via modulating Akt/FOXO1 pathway in renal cell carcinoma cells

• Published in: Biochemical and biophysical research communications Vol. 520; no. 1; pp. 1 - 7
• Main Authors: Kong, Zhenzhen, Guo, Xinming, Zhao, Zhijian, Wu, Weizhou, Luo, Lianmin, Zhu, Zhiguo, Yin, Shanfeng, Cai, Chao, Wu, Wenqi, Wang, Ding, Liu, Yongda, Duan, Xiaolu
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 26.11.2019
• Subjects: Akt/FOXO1 pathway; Cell growth; Renal cell carcinoma; SPTLC1; Cell growth; SPTLC1; Akt/FOXO1 pathway; Renal cell carcinoma
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2019.09.073

Serine palmitoyltransferase long chain-1 (SPTLC1), which is the rate-limiting enzyme for sphingolipid biosynthesis, has been indicated to be essential for carcinoma cell survival and proliferation in recent, but its role in the regulation of renal cell carcinoma (RCC) remains unknown. In the present study, we found that SPTLC1 expression was significantly decreased in RCC tissues compared to non-tumor tissues, and low SPTLC1 expression was associated with poor overall survival of RCC patients. In addition, our results revealed that forced expression of SPTLC1 could significantly inhibit cell growth in vitro and in vivo via, at least in part, modulating Akt/FOXO1 signaling pathway, thus representing a novel role of SPTLC1 in the regulation of tumor growth in RCC for the first time. •SPTLC1 expression was decreased in RCC tissues and predicts poor overall survival of RCC patients.•SPTLC1 could inhibit the cell growth of RCC cells in vitro and in vivo.•SPTLC1 inhibits the cell growth via modulating Akt/FOXO1 signal pathway in RCC cells.•SPTLC1 increases the activity and expression of FOXO1 in an Akt-depended manner.